Navigation Links
Data Published by Researchers from The Scripps Research Institute Demonstrate Potential for MYC Inhibitor Licensed by Sorrento Therapeutics
Date:8/18/2014

SAN DIEGO, Aug. 18, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that data published in the Proceedings of the National Academy of Sciences (PNAS)1 demonstrate the potential for the MYC inhibitors that Sorrento licensed from The Scripps Research Institute (TSRI)2. The TSRI research team, led by Professors Kim D. Janda and Peter K. Vogt, reported in the study that function of the MYC regulator could be inhibited with small molecule compounds in cell culture and importantly in an experimental cancer animal model.

The MYC protein is a transcriptional factor, meaning it controls gene expression and has been recognized as an important determinant of cancer metabolism and protein synthesis. It is involved as a dominant factor in most human cancers and is rarely mutated, but rather its "gain of function" results from overexpression or gene amplification. Abnormal MYC activity is believed to be a key factor in breast, lung, colon, hematologic and other cancers, including Burkitt's lymphoma, a fast-growing cancer that tends to strike children.

The small molecule MYC inhibitors interfere with the protein-protein interaction (PPI) between MYC and its obligatory dimerization partner, Max, preventing sequence-specific binding to DNA and subsequent initiation of oncogenic transformation. The unregulated expression of genes involved in cell proliferation, a key step in cancer growth, follows.

On July 21, 2014, Sorrento announced that preclinical development of a MYC inhibitor would be supported by a Phase 1 Small Business Technology Transfer Research (STTR) grant received from the National Cancer Institute (NCI), a division of the National Institutes of Health (NIH).

Professor Vogt, who is the EVP, CSO, & Professor at TSRI, co-discoverer of the MYC, jun, PI3K, & src oncogenes, and Sorrento's collaborator on this project, noted earlier2 that "MYC has also been called the 'emperor of oncogenes'. Targeting MYC with a small molecule inhibitor has been a daunting challenge and has given rise to the current dogma that MYC is 'undruggable'. Numerous studies have strengthened MYC's candidacy as a promising cancer drug target and also suggest that MYC inhibition might be therapeutic in many or most cancer types, irrespective of the underlying driving oncogenic mechanism. This clearly enhances the significance and importance of this potential scientific breakthrough."

"Based on its dominant role in multiple forms of cancer, it is widely acknowledged that MYC is a very important but yet unsuccessfully pursued target for cancer therapy. We are excited to have these potent and unique inhibitors in our development portfolio," said Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento. "In addition, the funding from the NCI STTR grant will allow us to dedicate research support without diverting resources from other programs in our pipeline, such as the clinical development activities for Cynviloq™ and RTX."

About Sorrento Therapeutics, Inc.

Sorrento is an oncology company developing new treatments for cancer and associated pain. Sorrento's most advanced asset Cynviloq™, the next-generation paclitaxel, commenced its registrational trial in March 2014 and is being developed under the abbreviated 505(b)(2) regulatory pathway. Sorrento is also developing RTX, a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. The Company has made significant advances in developing human monoclonal antibodies, complemented by a comprehensive and fully integrated antibody drug conjugate (ADC) platform that includes proprietary conjugation chemistries, linkers, and toxic payloads. Sorrento's strategy is to enable a multi-pronged approach to combating cancer with small molecules, mono- and bispecific therapeutic antibodies, and ADCs.

More information is available at www.sorrentotherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about commencing its Cynviloq registrational trial; and the advances made in developing human monoclonal antibodies, if any; and other matters that are described in Sorrento's Annual Report on Form 10-K for the year ended December 31, 2013, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law. 

1 http://www.pnas.org/content/early/2014/08/07/1319488111.abstract
Inhibitor of MYC identified in a Krohnke pyridine library
Jonathan R. Hart, Amanda L. Garner, Jing Yu, Yoshihiro Ito, Minghao Sun, Lynn Ueno, Jin-Kyu Rhee, Michael M. Baksh, Eduard Stefan, Markus Hartl, Klaus Bister, Peter K. Vogt, and Kim D. Janda; PNAS 2014; published ahead of print August 11, 2014, doi:10.1073/pnas.1319488111
2 http://sorrentotherapeutics.com/news/news-display/?id=122544



'/>"/>
SOURCE Sorrento Therapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers
2. Newly-Published Study Confirms Stretta to be Valuable GERD Treatment
3. Newly Published Survey Shows Drug Shortages Still Have Major Impact on Patient Care
4. Romosozumab Phase 2 Data Published In New England Journal Of Medicine Show Significant Increases In Bone Mineral Density At Both Spine And Hip
5. Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
6. Paper Published in American Journal of Cardiology Demonstrates Favorable Vascular Healing Following MiStent SES Implantation
7. New Findings Published In Circulation: Heart Failure Show Potential Utility Of Cardioxyls HNO Donors As Novel Treatments For Heart Failure
8. Case Report on 14-Year-Old Pediatric Patient Bridged to Transplant with SynCardia Total Artificial Heart Published in the Journal Perfusion
9. KaloBios KB001 Anti-Pseudomonas Antibody Study Published in Pediatric Pulmonology
10. New Edition of Popular Guide to Health Economic Evaluation Published by OHE
11. Newly-Published Study Concludes Stretta May Be More Desirable GERD Treatment than Chronic PPI Use or Anti-Reflux Surgery in Some Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... Calif. , March 1, 2017   Sun Chlorella ... about all things chlorella, is pleased to announce Non-GMO Project ... premium chlorella powder. Just in time for the ... in Anaheim, CA , Sun Chlorella Corp. ... all chlorella products, including: Sun Chlorella ...
(Date:3/1/2017)... 2017  Integrated Modular Design (IMD), a ... implementation of pre-fabricated healthcare products like bathroom ... seeks to lead the construction industry toward ... Fueled by their leading-edge pre-fabrication solutions, ... construction timelines and project risk, and increasing ...
(Date:3/1/2017)... 1, 2017  Global biotherapeutics leader CSL Behring ... ever Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trial, known as ... reatment with H izentra ® ).  The Phase ... safety and tolerability of two different doses of CSL ... Subcutaneous [Human]), compared with placebo, in the maintenance treatment ...
Breaking Medicine Technology:
(Date:3/1/2017)... ... March 01, 2017 , ... ... permanently embedded anti-odor solution to cotton knit and woven fabrics. , Retail ... maintaining the luxurious look and feel of cotton. Cotton Incorporated has developed ...
(Date:3/1/2017)... HILLS, CA (PRWEB) , ... March 01, 2017 , ... ... cryoablation for the treatment of early stage breast cancer and where it fits in ... Genes & The Choices We Make .” The event brings together leading cancer and ...
(Date:3/1/2017)... ... March 01, 2017 , ... Expert on international living and leading a ... & Go. , Time & Go app is the ultimate strategic compass that helps ... time management methods enable people to work smarter, not harder, that's why Time & ...
(Date:3/1/2017)... York, NY & Greenwich, CT (PRWEB) , ... March 01, 2017 ... ... many runners, especially in the winter months when people don’t want to stop training ... the knees – and setting the treadmill to a small incline can help protect ...
(Date:3/1/2017)... ... March 01, 2017 , ... “McFarnia”: a suspenseful tale of ... truth about his life and mysterious disappearance. “McFarnia” is the creation of published author ... North Carolina. He currently serves as a Chaplain with Transport for Christ at a ...
Breaking Medicine News(10 mins):